September
Pro Medicus’ billionaire boss says simplicity secret of success
Pro Medicus’ stranglehold on cloud-imaging healthcare tech means its growth trajectory has a long way to go.
- Michael Smith
Nordic PE firm comes calling for Melbourne life sciences biz IonOpticks
The deal comes after this column revealed IonOpticks had mandated Rothschild to run a strategic review, with expectations of a circa $160 million valuation.
- Sarah Thompson, Kanika Sood and Emma Rapaport
August
- Exclusive
- Venture capital
How this research institute turned cancer success into a $66m VC fund
After banking $US325m from co-developing a blockbuster cancer drug, WEHI has begun making start-up investments seeking scientific breakthroughs from a new $66m fund.
- Tess Bennett
- Analysis
- Higher Education Awards
Winning strategy: Love hormone research bears multimillion-dollar deal
Comment provided by the joint winners of the Research Commercialisation award, the University of Sydney and UNSW.
- Michael Kassiou and Guan Heng Yeoh
- Opinion
- Chanticleer
‘I want to win every time’: The Olympic-style goal driving CSL’s boss
The company’s growth forecasts for next year are a touch weaker than the market expected. But inspired by the Games, CEO Paul McKenzie is focused on another goal.
- Updated
- James Thomson
Billionaire Salesforce boss tips into Sydney biotech incubator
Along with Marc Benioff, World Bank president Ajay Banga and Melbourne’s Churchill Asset Management all put in for a round that values the firm at $90 million.
- Sarah Thompson, Kanika Sood and Emma Rapaport
July
Heart medtech Anteris Technologies in $40m raise
The proceeds would fund development of its flagship DurAVR THV product which aims to mimic a healthy aortic valve.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Imricor Medical Systems in $35m raise
A presentation sent to potential backers said Imricor had spent 18 years and $US105 million ($155.7 million) on its technology.
- Sarah Thompson, Kanika Sood and Emma Rapaport
June
How China became a scientific superpower
From plant biology to superconductor physics, the country is at the cutting edge.
- The Economist
Radiopharm in $65m raise; Nasdaq-listed strategic pays 47pc premium
Diagnostics specialist Lantheus, capitalised at $8 billion on the Nasdaq, likes the look of Aussie company Radiopharm Theranostics.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Aussie high-flyer’s wings clipped by US investors
Red-hot biotech Telix got a shock when US investors wanted a chunky discount to buy stock. So it’s walking away looking silly, but with its pride intact.
- Anthony Macdonald
Opthea launches $220 million capital raising, MST on ticket
The biotech has high hopes for a new drug that if successful could treat macular degeneration.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Telix greenlights $300m Nasdaq listing in search for deep pockets
It is the second ASX-listed growth stock to flag intentions to list in New York, with Life360, the developer of family social media apps, to debut overnight.
- Joshua Peach
- Exclusive
- Funding
Aussie vaccine start-up scores $300m valuation
GPN Vaccines has raised $18 million in a round led by Forepont Capital and Kern Capital.
- Yolanda Redrup
- Exclusive
- Funding
Super funds, CSL pour $270m into venture capital fund
Australia’s largest life science investment fund, Brandon Capital, has banked $270 million of a planned $350 million raise for its sixth VC fund.
- Updated
- Tess Bennett
Chris Abbott-backed Genetic Signatures raises $30 million
There’s an FDA approval in the bag, and a CEO replacement for long-standing boss John Melki has been found. And of course, the stock is up 78 per cent year to date.
- Sarah Thompson, Kanika Sood and Emma Rapaport
BCAL Diagnostics closes oversubscribed raise; Ellerston tops up
Sources said BCAL has initially sought $5 million, but was able to raise twice that amount based on the demand.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Investment banker David Williams still going rogue
“We were not aware he would say such things,” the Bionic Institute’s Robert Klupacs wrote in his apology.
- Updated
- Myriam Robin
May
Replica Ozempic ban could deny thousands ‘life-changing medication’
Healthcare start-ups say the ban is a step too far and risks leaving tens of thousands of Australians without the medications they need.
- Euan Black and Paul Smith
TPG Capital wines and dines LPs ahead of Novotech exit
We imagine TPG’s LPs would be pushing to get answers on two of the firm’s biggest investments Down Under: Greencross and Novotech.
- Sarah Thompson, Kanika Sood and Emma Rapaport